NVS - POINT Biopharma trades through deal price with Eli Lilly
2023-10-18 13:16:41 ET
More on POINT Biopharma Global
- Eli Lilly POINTs Toward Radiopharmaceutical Ambitions
- POINT Biopharma: Leading The Future Of Radioligand Therapy
- POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials
- Eli Lilly to acquire Point Biopharma in $1.4B deal (update)
- Biggest stock movers today: NextEra Energy Partners, WeWork, ALX Oncology, POINT Biopharma and more
For further details see:
POINT Biopharma trades through deal price with Eli Lilly